Vascular Biogenics Ltd (VBLT)

[koman]

Question for this board: Why is this company trying to change their SPA statistical plan by increasing the total events for the interim as well as the final? Was the last conference call the first time that this plan of change was mentioned? I like the prospects of this company but I try to look for any negatives to measure the risk. Usually, in my view, a change is a negative but in this case I wonder if the reason was due to the speed of enrollment. But also, this trial is an open label trial so that the comment concerning not as many events makes me a little cautious that the ctrl arm will end up doing much better than historical data. I'd appreciate any comments from those more knowledgable concerning this stock. TIA